4.6 Review

COVID-19 Associated Hypercoagulability: Manifestations, Mechanisms, and Management

期刊

SHOCK
卷 55, 期 4, 页码 465-471

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/SHK.0000000000001660

关键词

Coagulation; coronavirus; COVID-19; embolism; thrombosis

向作者/读者索取更多资源

Patients with severe COVID-19 often develop hypercoagulability, which can improve with anticoagulant therapy. Viscoelastic coagulation testing provides an opportunity to tailor anticoagulant therapy based on individual coagulation status.
Patients with severe coronavirus disease-2019 (COVID-19) frequently have hypercoagulability caused by the immune response to the severe acute respiratory syndrome coronavirus-2 infection. The pathophysiology of COVID-19 associated hypercoagulability is not fully understood, but characteristic changes include: increased fibrinogen concentration, increased Factor VIII activity, increased circulating von Willebrand factor, and exhausted fibrinolysis. Anticoagulant therapy improves outcomes in mechanically ventilated patients with COVID-19 and viscoelastic coagulation testing offers an opportunity to tailor anticoagulant therapy based on an individual patient's coagulation status. In this narrative review, we summarize clinical manifestations of COVID-19, mechanisms, monitoring considerations, and anticoagulant therapy. We also review unique considerations for COVID-19 patients who are on extracorporeal membrane oxygenation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据